User:Toxprojectradboud/sandbox

Reldesemtiv is a compound created by Cytokinetics Inc. This biopharmaceutical company is focused on the development of muscle activators to treat the people suffering from impaired or declining muscle function diseases, such as SMA (Spinal Muscular Atrophy). Reldesemtiv is currently being developed in collaboration with Astellas, which owns the exclusive license for its commercialization worldwide.

A first generation FSTA, tirasemtiv, was developed before reldesemtiv, although it was suspended after unsuccessful tests in Phase 3 clinical trial VITALITY-ALS, where its effects on respiratory function and muscle strength in people with ALS. In comparison with it, Reldesemtiv appears to be more potent and produced larger increases in force than did tirasemtiv in similar pharmacodynamic studies, supporting improvements of muscle function on treated individuals.

Reldesemtiv is still under clinical trials. It has been subjected to five different Phase 1 clinical trials, where its pharmacokinetics and pharmacodynamics were evaluated, and it succeeded proving safety, bioavailability and tolerability

(John Wiley & Sons, Inc.).